Link to this page
National Cancer Institute Thesaurus
| Preferred Name | Ezetimibe | |
| Synonyms |
1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone EZETIMIBE Ezedoc Ezetimibe Zetia |
|
| Definitions |
An azetidinone derivative and a cholesterol absorption inhibitor with lipid-lowering activity. Ezetimibe appears to interact physically with cholesterol transporters at the brush border of the small intestine and inhibits the intestinal absorption of cholesterol and related phytosterols. As a result, ezetimibe causes a decrease in the level of blood cholesterol or an increase in the clearance of cholesterol from the bloodstream. Overall, the following effects observed are a reduction of hepatic cholesterol stores and a reduction of total cholesterol, LDL cholesterol, and other triglycerides in the blood. |
|
| ID |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C47529 |
|
| ALT_DEFINITION |
A cholesterol absorption inhibitor with lipid-lowering activity
|
|
| CAS_Registry |
163222-33-1
|
|
| CHEBI_ID |
CHEBI:49040
|
|
| Chemical_Formula |
C24H21F2NO3
|
|
| code |
C47529
|
|
| Concept_In_Subset |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C176424 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C191670 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C191200 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116978 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C116977 http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C191387 |
|
| Contributing_Source |
ACC/AHA CTRP FDA
|
|
| DEFINITION |
An azetidinone derivative and a cholesterol absorption inhibitor with lipid-lowering activity. Ezetimibe appears to interact physically with cholesterol transporters at the brush border of the small intestine and inhibits the intestinal absorption of cholesterol and related phytosterols. As a result, ezetimibe causes a decrease in the level of blood cholesterol or an increase in the clearance of cholesterol from the bloodstream. Overall, the following effects observed are a reduction of hepatic cholesterol stores and a reduction of total cholesterol, LDL cholesterol, and other triglycerides in the blood.
|
|
| Display_Name |
Ezetimibe
|
|
| FDA_UNII_Code |
EOR26LQQ24
|
|
| FULL_SYN |
1-(4-fluorophenyl)-3(R)-[3-(4-fluorophenyl)-3(S)-hydroxypropyl]-4(S)-(4-hydroxyphenyl)-2-azetidinone EZETIMIBE Ezedoc Ezetimibe Zetia
|
|
| Has_ACC-AHA_SARS2_Authorized_Value |
http://ncicb.nci.nih.gov/xml/owl/EVS/Thesaurus.owl#C17998 |
|
| label |
Ezetimibe
|
|
| Legacy Concept Name |
Ezetimibe
|
|
| NCI_Drug_Dictionary_ID |
754008
|
|
| PDQ_Closed_Trial_Search_ID |
754008
|
|
| PDQ_Open_Trial_Search_ID |
754008
|
|
| Preferred_Name |
Ezetimibe
|
|
| prefixIRI |
Thesaurus:C47529
|
|
| Semantic_Type |
Pharmacologic Substance
|
|
| UMLS_CUI |
C1142985
|
|
| subClassOf |
| Delete | Subject | Author | Type | Created |
|---|---|---|---|---|
| No notes to display |